TrialFrontiers in immunology2024

Efficacy and safety of second-line therapy by S-1 combined with sintilimab and anlotinib in pancreatic cancer patients with liver metastasis: a single-arm, phase II clinical trial.

Xin Qiu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.